🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

In non-critically ill patients with COVID-19, therapeutic-dose anticoagulation reduced organ support, thrombosis, and death by 28 days, but increased bleeding risk (though absolute risk stayed low). No high-credibility effect modifiers found. Great work Tobias Tritschler! #ISTH2025

ISTH is inviting all clinicians involved in anticoagulation management to participate in the following survey: redcap.slhd.nsw.gov.au/surveys/?s=7K4… These are the outcomes they are interested in. Jump on the link and fill it out! #ISTH2025 THANZ

Full house at the #ISTH2025 opening ceremony featuring @ISTH President PantepAngchaisuksiri

The stage is set! 🔥 🐉 Join us today at 12:15 pm ET for the 2025 Dragons' Den Competition at #ISTH2025 in Room 203 A&B Watch three clinical investigators pitch their #VTE studies for a chance at a $40K collaboration prize! mailchi.mp/0edcd914afba/i…

At #ISTH25 ? Don't miss Dr. Lana Castellucci present on the practice-changing COBRRA Trial (Comparison of Bleeding Risk between Rivaroxaban and Apixaban in Acute Venous Thromboembolism) in the LB 01 - Late-Breakthrough session I Time: 9:30 AM ET Room: Ballroom A-C #Thrombosis

Is this the end of rivaroxaban for acute VTE? Lana Castellucci presenting the COBBRA trial - 1st RCT comparing apixaban to riva over 3 months. 56% reduction in bleeding risk with apixaban. A safer Rx with the same efficacy. #ISTH2025

Late breaking abstract session at #ISTH2025. COBRRA results are in! 50% reduction in bleeding with Apixaban use for acute VTE compared to Rivaroxaban. THANZ members were co-investigators on this study, an enormous effort.

Amazing achievement 😱 Congratulations Lana Castellucci and Al the CanVECTOR Network network 👏

THANZ Congratulations Lana Castellucci and the entire study team ! Incredible work on this pivotal trial !

Hot off the press! COBBRA trial showed that apixaban is associated with >50% reduced risk of clinically-relevant bleeding symptoms for acute VTE treatment. This can be practice changing! Lana Castellucci Marc Rodger CanVECTOR Network

Starting soon ! Join us in room 203 A&B or via the live stream below m.youtube.com/watch?v=UAfNAL…

🩸 Meta-analysis presented at #ISTH2025 and simultaneously published in EHJ Editor-in-Chief found that several risk factors (e.g., previous history of VTE or bleeding, advanced cancer, and specific cancer sites) are associated with recurrent VTE and bleeding in patients with CAT.

🫁 A COPD-specific diagnostic strategy for PE was retrospectively validated and found to be safe using a 3-item score + D-dimer with 2 cut-offs, 50% of patients avoided imaging. 🔍 Signs of DVT, non-purulent AECOPD, and PE as most likely dx #ISTH2025 #VTE #COPD

🩸 Clots tend to come back at the same site as the index VTE! Among 708 patients with prior VTE, recurrences often occurred at the same site as the original event, especially ipsilateral DVTs. Familiar symptoms? Trust your clinical instincts. #ISTH2025 #VTE #DVT

At #ISTH2025 ? Don’t miss Prof. Le Gal present on the network endorsed Adjust-#DVT study at 10:30 am ET in room 146 A-C. An incredible multi-national research achievement! #thrombosis #research

📢 Practice-changing data from the Adjust-DVT study! ✅ Age-adjusted D-dimer safely rules out DVT in low/non-high pretest probability patients 📉 Reduces unnecessary ultrasounds 🔍 +17% yield in patients ≥75 years #ISTH2025 #DVT #Thrombosis #LessIsMore

🩸 New insights from the RENOVE trial (extended duration anticoagulation) at #ISTH2025: 📉 Reduced-dose DOAC is non-inferior in patients with BMI <30, with less bleeding risk. ⚠️ But in patients with BMI ≥30, reduced-dose may be inferior for bleeding and recurrent VTE. ➡️

🚨 SPECTACULAR RCT at #ISTH2025! Although non-inferiority to CTPA wasn’t shown, a negative SPECT V/Q scan led to low 3-month VTE risk ✅ Supporting the safety of ruling out PE with a SPECT-based algorithm SPECTacular findings indeed! 🫁💥

Be part of a research planning meeting focusing on reducing the risk of #thrombosis us02web.zoom.us/meeting/regist…

🫁 Derivation and Validation of a COPD-specific Pulmonary Embolism Diagnostic Strategy ⬇️ 📌 Mai et al. derived a #COPD-specific algorithm 📌 Diagnostic failure rate: 0.9%; 53.4% patients would need imaging to rule out #PE 👉 thieme-connect.de/products/ejour… #VTE #Thrombosis